Table 1.
Demographics of the 141 participants included in the TRIAD CSF cohort.
| TRIAD cohort (n = 141) | CU− (n = 50) | CU+ (n = 32) | MCI+ (n = 20) | AD (n = 20) | Non‐AD (n = 19) | P‐value |
|---|---|---|---|---|---|---|
| Females, n (%) | 31 (62.0) | 21 (65.6) | 9 (45.0) | 9 (45.0) | 9 (47.4) | 0.35 |
| Age, mean (SD) | 70.3 (8.7)# | 73.0 (4.2)# | 72.2 (7.2) # | 64.1 (7.4)* | 66.2 (9.7) | ˂0.0001 |
| Education years, mean (SD) | 15.3 (3.4) | 14.0 (3.0) | 15.7 (15.9) | 15.4 (3.1) | 14.4 (3.8) | 0.28 |
| APOE‐ɛ4 carriers, n (%) | 13 (26)# | 12 (37.5) | 13 (65)* | 13 (65)* | 3 (15.8)# | ˂0.001 |
| MMSE score, mean (SD) | 29.3 (1.0)# | 29.1 (0.9)# | 28.0 (1.8)# | 19.8 (6.2)* | 26.8 (5.2)# | ˂0.0001 |
| Aβ PET (SUVR), mean (SD) | 1.27 (0.13)# | 1.82 (0.48)*# | 2.39 (2.42)* | 2.39 (0.45)* | 1.24 (0.12)# | ˂0.0001 |
| Tau PET (SUVR), mean (SD) | 0.90 (0.10)# | 1.00 (0.14)# | 1.55 (1.45)*# | 2.14 (0.57)* | 0.83 (0.11)# | ˂0.0001 |
| CSF Aβ1–42/40 (pg/ml), mean (SD) | 0.09 (0.01)# | 0.05 (0.01)*# | 0.04 (0.01)*# | 0.04 (0.01)* | 0.09 (0.01)# | ˂0.0001 |
| CSF p‐tau217 (pg/ml), mean (SD) | 5.1 (3.1)# | 13.7 (16.4)*# | 24.3 (10.2)*# | 29.1 (22.0)* | 4.7 (2.1)# | ˂0.0001 |
| CSF p‐tau231 (pg/ml), mean (SD) | 9.1 (2.4)# | 20.8 (16.3)*# | 31.6 (14.1)*# | 37.4 (24.7)* | 9.1 (3.9)# | ˂0.0001 |
| CSF p‐tau235 (pg/ml), mean (SD) | 13.1 (3.6)# | 17.4 (7.0)*# | 26.5 (7.4)* | 28.6 (11.0)* | 12.7 (3.1)# | ˂0.0001 |
CU, cognitively unimpaired; MCI, mild cognitive impairment; AD, Alzheimer’s disease; MMSE, Mini Mental State Examination; PET, positron emission tomography; SUVR, standardised uptake value ratio; CSF, cerebrospinal fluid; Aβ, amyloid‐beta; SD, standard deviation.
Data are presented as mean (SD). Differences between groups were tested using one‐way ANOVA adjusted by age and sex, followed by Bonferroni‐corrected post‐hoc comparison (continuous variables) or Fisher exact test (categorical variables). Significant differences compared with CU− (*) and AD (#).